Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital Trends
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

Breyanzi

Cell_Gene_Therapy

Cell and Gene Therapy Today—December 11, 2025

This week’s Cell & Gene Therapy update highlights two major FDA approvals…

Hematology

Hematology Today—December 8, 2025

This week in Hematology, we spotlight the most relevant updates, approvals, and…

Hematology

Hematology Today—December 1, 2025

This week’s hematology news covers key regulatory milestones, access decisions,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Oncology Today—January 26, 2026
AI in Healthcare and Digital Health Video Recap —January 26, 2026
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
AI in Healthcare and Digital Health Today—January 26, 2026
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development

Tags

AB Science adolescent smartphone exposure arrhythmias B-cell architecture analysis Bluejay Therapeutics Canada National Strategy for Drugs for Rare Diseases cancer Celea Therapeutics clinical validation Congenital disorder of glycosylation CorEvitas Coronary artery calcium depemokimab Drug Development Innovation Elranatamab enterprise AI Fruzaqla Global obesity market HBICE Hematologic malignancies hematology HSA Huons INHALE 1 study ivc thrombectomy LUMC mavacamten Medical Care Technologies metastatic uveal melanoma Monoclonal antibodies Myocarditis neuroinflammatory diseases NIHR Southampton non viral vectors pharma Pluristyx Prurigo nodularis Relutrigine rosacea Rubraca Sema4 Stem-cell diabetes therapy T-cell engager Tessera Therapeutics Zika vaccine

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Oncology Today—January 26, 2026
AI in Healthcare and Digital Health Video Recap —January 26, 2026
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
AI in Healthcare and Digital Health Today—January 26, 2026
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development

TAGS

AB Science adolescent smartphone exposure arrhythmias B-cell architecture analysis Bluejay Therapeutics Canada National Strategy for Drugs for Rare Diseases cancer Celea Therapeutics clinical validation Congenital disorder of glycosylation CorEvitas Coronary artery calcium depemokimab Drug Development Innovation Elranatamab enterprise AI Fruzaqla Global obesity market HBICE Hematologic malignancies hematology HSA Huons INHALE 1 study ivc thrombectomy LUMC mavacamten Medical Care Technologies metastatic uveal melanoma Monoclonal antibodies Myocarditis neuroinflammatory diseases NIHR Southampton non viral vectors pharma Pluristyx Prurigo nodularis Relutrigine rosacea Rubraca Sema4 Stem-cell diabetes therapy T-cell engager Tessera Therapeutics Zika vaccine

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital Trends
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy